Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Issue 4 (14th April 2015)

• Record Type: Journal Article
• Authors: Gunduz, Seyda; Mutlu, Hasan; Tural, Deniz; Yıldız, Özcan; Uysal, Mukremin; Coskun, Hasan Senol; Bozcuk, Hakan
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 11:Issue 4(2015:Dec.)
• Page Start: 288
• Page End: 292
• Publication Date: 2015-04-14
• Subjects: Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.12358
• Languages: English
• ISSNs: 1743-7555

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="ajco12358-sec-0001" sec-type="section"> <title>Aim</title> <p>The objective of this study was to evaluate the blood platelet–lymphocyte ratio (PLR) for its prognostic value in patients with metastatic renal cell cancer (RCC).</p> </sec> <sec id="ajco12358-sec-0002" sec-type="section"> <title>Methods</title> <p>We retrospectively reviewed 100 patients diagnosed with metastatic RCC previously treated with tyrosine kinase inhibitors from three centers. We assessed the prognostic value of pretreatment PLR and other clinical and laboratory parameters based on univariate and multivariate analyses.</p> </sec> <sec id="ajco12358-sec-0003" sec-type="section"> <title>Results</title> <p>Median progression‐free survival (PFS) was 7.3 months and median overall survival (OS) was 15.3 months. Multivariate analysis revealed that PFS is significantly affected by ECOG PS (<italic>P</italic> = 0.047), PLR (<italic>P</italic> = 0.029) and calcium level (<italic>P</italic> = 0.023). Median PFS was 13.9 versus 5.3 months in patients with PLR ≤ 210 versus PLR > 210 (log rank; <italic>P</italic> = 0.001). Median OS was 25.9 versus 10.9 months with PLR ≤ 210 versus PLR > 210 (log rank; <italic>P</italic> = 0.013).</p> </sec> <sec id="ajco12358-sec-0004" sec-type="section"> <title>Conclusions</title> <p>This study shows that increased pretreatment PLR is an independent prognostic indicator in patients with metastatic RCC who use tyrosine kinase inhibitors.</p> </sec> </abstract>